(0.34%) 5 117.13 points
(0.31%) 38 356 points
(0.38%) 15 989 points
(-0.86%) $83.13
(5.82%) $2.04
(0.43%) $2 357.40
(0.46%) $27.66
(3.92%) $958.25
(-0.22%) $0.933
(-0.37%) $10.98
(-0.54%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA...
Stats | |
---|---|
本日の出来高 | 245 298 |
平均出来高 | 564 056 |
時価総額 | 0.00 |
EPS | $0 ( 2023-03-13 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0.0560 (0.37%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-01-19 | Bate Kenneth | Sell | 375 | Common Stock |
2023-01-19 | Bate Kenneth | Sell | 22 500 | Stock Option (Right to Buy) |
2023-01-19 | Evnin Anthony B | Sell | 22 500 | Stock Option (Right to Buy) |
2023-01-19 | Ledell Jebediah | Sell | 27 702 | Stock Option (Right to Buy) |
2023-01-19 | Ferraresso Michael | Sell | 220 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
46.33 |
Last 96 transactions |
Buy: 43 011 518 | Sell: 9 966 796 |
ボリューム 相関
Aveo Pharmaceuticals Inc 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Aveo Pharmaceuticals Inc 相関 - 通貨/商品
Aveo Pharmaceuticals Inc 財務諸表
Annual | 2021 |
収益: | $38.87M |
総利益: | $34.14M (87.81 %) |
EPS: | $-2.49 |
FY | 2021 |
収益: | $38.87M |
総利益: | $34.14M (87.81 %) |
EPS: | $-2.49 |
FY | 2020 |
収益: | $6.02M |
総利益: | $4.77M (79.32 %) |
EPS: | $-1.660 |
FY | 2019 |
収益: | $28.80M |
総利益: | $0.00 (0.00 %) |
EPS: | $0.610 |
Financial Reports:
No articles found.
Aveo Pharmaceuticals Inc
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。